SCHEMBL5585565

SCHEMBL5585565

O=C(O)c1ccc(Nc2nc(-c3ccc(OCc4ccc(-c5ccccc5)cc4)cc3)cs2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 9/20 0.71
RAB9A P51151 4/20 0.70
MEN1 O00255 4/20 0.70
KMT2A Q03164 4/20 0.70
NPC1 O15118 3/20 0.70
MAPT P10636 3/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
CSNK2A2 P19784 1/20 0.57
CSNK2B P67870 1/20 0.57
CSNK2A3 Q8NEV1 1/20 0.57
ALOX5 P09917 4/20 0.56
AMY1A P0DUB6 1/20 0.56
VCP P55072 1/20 0.56
GAA P10253 2/20 0.56
NFKB1 P19838 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
RECQL P46063 1/20 0.56
CFTR P13569 1/20 0.54
HPGDS O60760 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5585418 0.86 CSNK2A1 (0.62) CSNK2A1RAB9AMEN1KMT2ANPC1
SCHEMBL5585929 0.85 CSNK2A1 (0.58) CSNK2A1RAB9AMEN1KMT2ANPC1
SCHEMBL13193327 0.85 FFAR1 (0.58) CSNK2A1RAB9AMEN1KMT2ANPC1
SCHEMBL1818544 0.84 CSNK2A1 (1.00) CSNK2A1RAB9AMEN1KMT2ANPC1
SCHEMBL248227 0.80 CSNK2A1 (0.70) CSNK2A1RAB9AMEN1KMT2ANPC1
SCHEMBL7114838 0.80 CSNK2A1 (0.56) CSNK2A1RAB9AMEN1KMT2ANPC1
SCHEMBL5585573 0.79 CSNK2A1 (0.61) CSNK2A1RAB9AMEN1KMT2ANPC1
SCHEMBL5582767 0.78 NR4A2 (0.81) RAB9ANPC1SMN1; SMN2ALOX5
SCHEMBL1756343 0.78 NR4A2 (0.81) RAB9ANPC1SMN1; SMN2ALOX5
SCHEMBL5585544 0.78 NR4A2 (0.57) RAB9ANPC1SMN1; SMN2ALOX5GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7163952-B2 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2007-01-16 US disclosed
US-7163952-B2 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2007-01-16 US disclosed
US-20050065196-A1 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2005-03-24 US disclosed
EP-1452530-A1 AZOLE COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065196-A1 Azole compound and medicinal use thereof PTPN7, PTPN1, PTPN5 CSNK2A1 124/4885RAB9A 1736/4885MEN1 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.